Cargando…

In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats

Diabetes mellitus is a metabolic syndrome considered one of the life-threatening diseases in the last two decades. This research aimed to investigate the anti-diabetic potential of bitter honey collected from Nilgiris using both in vitro and in vivo methods. The mineral content of bitter honey was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koodathil, Joshna, Venkatachalam, Gopal, Bhaskaran, Kavitha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979185/
https://www.ncbi.nlm.nih.gov/pubmed/36873120
http://dx.doi.org/10.25122/jml-2022-0099
_version_ 1784899674613743616
author Koodathil, Joshna
Venkatachalam, Gopal
Bhaskaran, Kavitha
author_facet Koodathil, Joshna
Venkatachalam, Gopal
Bhaskaran, Kavitha
author_sort Koodathil, Joshna
collection PubMed
description Diabetes mellitus is a metabolic syndrome considered one of the life-threatening diseases in the last two decades. This research aimed to investigate the anti-diabetic potential of bitter honey collected from Nilgiris using both in vitro and in vivo methods. The mineral content of bitter honey was also estimated using atomic absorption spectrophotometer. Bitter honey had a higher amount of zinc and copper, while heavy metals like lead, nickel, and cadmium were below the detection limit. The in vitro antidiabetic study was performed using alpha-amylase and alpha-glucosidase inhibition methods. Acute toxicity (OECD 423) was conducted in female Wistar rats to determine the lethal dose of bitter honey. The antidiabetic activity was carried out in type-2 diabetic Wistar Albino rats induced with streptozotocin and nicotinamide. The experimental rats were categorized into five groups (n=8): the normal group, the diabetic control group, standard glibenclamide-treated diabetic group, bitter honey 200 mg/kg, and 400 mg/kg b.w. treated diabetic group. After the treatment period (28 days), blood samples were collected for biochemical studies, and the pancreas was dissected for histopathological studies. The in vitro antidiabetic studies revealed the antidiabetic potential of bitter honey compared to standard acarbose. Treatment of diabetic rats with bitter honey revealed a statistically significant reduction (P<0.05) in the levels of fasting blood glucose (FBG) compared to untreated diabetic rats. This was accompanied by an elevated HDL and a decrease in LDL, VLDL, triglycerides, total cholesterol, SGOT, SGPT, urea, and creatinine. Histopathological changes in the pancreas indicated a marked improvement in a dose-dependent manner. The study concluded that bitter honey could potentially decrease the levels of FBG in diabetic rats and the various biochemical and histopathological abnormalities associated with diabetes mellitus.
format Online
Article
Text
id pubmed-9979185
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-99791852023-03-03 In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats Koodathil, Joshna Venkatachalam, Gopal Bhaskaran, Kavitha J Med Life Original Article Diabetes mellitus is a metabolic syndrome considered one of the life-threatening diseases in the last two decades. This research aimed to investigate the anti-diabetic potential of bitter honey collected from Nilgiris using both in vitro and in vivo methods. The mineral content of bitter honey was also estimated using atomic absorption spectrophotometer. Bitter honey had a higher amount of zinc and copper, while heavy metals like lead, nickel, and cadmium were below the detection limit. The in vitro antidiabetic study was performed using alpha-amylase and alpha-glucosidase inhibition methods. Acute toxicity (OECD 423) was conducted in female Wistar rats to determine the lethal dose of bitter honey. The antidiabetic activity was carried out in type-2 diabetic Wistar Albino rats induced with streptozotocin and nicotinamide. The experimental rats were categorized into five groups (n=8): the normal group, the diabetic control group, standard glibenclamide-treated diabetic group, bitter honey 200 mg/kg, and 400 mg/kg b.w. treated diabetic group. After the treatment period (28 days), blood samples were collected for biochemical studies, and the pancreas was dissected for histopathological studies. The in vitro antidiabetic studies revealed the antidiabetic potential of bitter honey compared to standard acarbose. Treatment of diabetic rats with bitter honey revealed a statistically significant reduction (P<0.05) in the levels of fasting blood glucose (FBG) compared to untreated diabetic rats. This was accompanied by an elevated HDL and a decrease in LDL, VLDL, triglycerides, total cholesterol, SGOT, SGPT, urea, and creatinine. Histopathological changes in the pancreas indicated a marked improvement in a dose-dependent manner. The study concluded that bitter honey could potentially decrease the levels of FBG in diabetic rats and the various biochemical and histopathological abnormalities associated with diabetes mellitus. Carol Davila University Press 2023-01 /pmc/articles/PMC9979185/ /pubmed/36873120 http://dx.doi.org/10.25122/jml-2022-0099 Text en ©2022 JOURNAL of MEDICINE and LIFE https://creativecommons.org/licenses/by/3.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Original Article
Koodathil, Joshna
Venkatachalam, Gopal
Bhaskaran, Kavitha
In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title_full In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title_fullStr In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title_full_unstemmed In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title_short In vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic Wistar rats
title_sort in vitro and in vivo antidiabetic activity of bitter honey in streptozotocin-nicotinamide-induced diabetic wistar rats
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979185/
https://www.ncbi.nlm.nih.gov/pubmed/36873120
http://dx.doi.org/10.25122/jml-2022-0099
work_keys_str_mv AT koodathiljoshna invitroandinvivoantidiabeticactivityofbitterhoneyinstreptozotocinnicotinamideinduceddiabeticwistarrats
AT venkatachalamgopal invitroandinvivoantidiabeticactivityofbitterhoneyinstreptozotocinnicotinamideinduceddiabeticwistarrats
AT bhaskarankavitha invitroandinvivoantidiabeticactivityofbitterhoneyinstreptozotocinnicotinamideinduceddiabeticwistarrats